Besides, it is comprehensible to suggest that enhanced levels of ICAM-1 in patients with ILD, regardless of whether they have RA-ILD+ or IPF, could be due to a compensatory response to lung damage. This evidence concerns the gene ICAM1 and interstitial lung disease.